Current and emerging treatment options for premature ejaculation.

Autor: Gul M; Department of Urology, Selcuk University School of Medicine, Konya, Turkey., Bocu K; Department of Urology, Silopi State Hospital, Sirnak, Turkey., Serefoglu EC; Department of Urology, Biruni University School of Medicine, Istanbul, Turkey. egecanserefoglu@hotmail.com.
Jazyk: angličtina
Zdroj: Nature reviews. Urology [Nat Rev Urol] 2022 Nov; Vol. 19 (11), pp. 659-680. Date of Electronic Publication: 2022 Aug 25.
DOI: 10.1038/s41585-022-00639-5
Abstrakt: Premature ejaculation (PE) is a prevalent male sexual dysfunction. Current standard treatment regimens include behavioural therapies, topical anaesthetics, dapoxetine and other selective serotonin reuptake inhibitors (SSRIs). Most of the pharmacotherapeutic options target neurotransmitters (such as serotonin and oxytocin) that have a role in the ejaculation mechanism. However, these treatments are mildly effective and only provide a temporary delay in the ejaculation latency time, and PE recurs when the treatment is stopped. Thus, a treatment for PE is urgently needed and research is ongoing to find the ideal PE therapy. The efficacy and safety of topical anaesthetics and SSRIs in delaying ejaculation have been confirmed in many well-designed controlled trials. Both preclinical and clinical studies on new-generation SSRIs are ongoing. Moreover, promising results came from clinical trials in which the efficacy of on-demand PE therapies targeting neurotransmitters other than serotonin, such as α1-adrenoceptor antagonists and oxytocin antagonists, was assessed. Surgical intervention and neuromodulation have been proposed as potential treatment options for PE; however, current PE guidelines do not recommend these treatments owing to safety concerns.
(© 2022. Springer Nature Limited.)
Databáze: MEDLINE
Externí odkaz: